A team of AI researchers and mathematicians affiliated with several institutions in the U.S. and the U.K. has developed a math benchmark that allows scientists to test the ability of AI systems to ...

Pepe Unchained is a new contender in the meme coin market, launching its own Layer 2 blockchain extension based on the popular Pepe coin. Recently, it has attracted considerable attention by raising ...

Gaia, a decentralized, open-source AI agent developer tool, has partnered with the restaking protocol EigenLayer to enhance decentralized AI security and scalability. According to the team ...

China is expected to play a leading role in creating a “quantum-proof” communication protocol, after scientists from the country presented a design blueprint at a major international ...

Tarsus Pharmaceuticals, Inc. (TARS) shares ended the last trading session 10.6% higher at $43.87. The jump came on an impressive volume with a higher-than-average number of shares changing hands ...

The public float for TARS is 31.79M, and currently, short sellers hold a 30.44% ratio of that floaft. The average trading volume of TARS on October 30, 2024 was 698.40K shares. 3 Tiny Stocks Primed to ...

TARS Protocol is an AI-driven, scalable Web3 modular infrastructure platform designed to empower projects with cutting-edge artificial intelligence solutions and one-stop BaaS (Blockchain-as-a-Service ...

Barclays analyst Balaji Prasad maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed last Friday at $39.41.